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Abstract 
Aims                                                                                                                                                                       
The aim of this study was to explore if international guidelines concerning diabetes care for children 
are followed, and if they are not, why, and how practice is different from the international 
recommendations. 
Methods                                                                                                                                                                                            
As part of their compulsory student thesis, medical students from the University of Oslo, Norway, 
made a standardized questionnaire based upon the International Society for Pediatric and 
Adolescent Diabetes (ISPAD) guidelines from 2009. A total of 16 hospitals in eight countries, six 
continents, were visited. Diabetes care in children was observed, and personnel at the hospitals were 
interviewed semi structured, based on the questionnaire.  
Results                                                                                                                                                                             
Out of 16 hospitals visited, all but the hospital in Rwanda reported that they used guidelines in their 
care for children with diabetes. Some used national guidelines, but these were quite similar to the 
ISPAD guidelines. Lack of medical equipment would make it hard to follow guidelines in Rwanda even 
if tried. The proportion of children with diabetic ketoacidosis at diagnosis varied from six to 100%. All 
hospitals but the one in Rwanda used treatment goals measured in glycosylated hemoglobin. The 
amount of patients reaching the treatment goal varied from 9-65%. Countries without registries for 
incidence and complications generally reported a higher rate of success in diabetes care. At the same 
time some reported treating children with late diabetes complications. 
Conclusions                                                                                                                                                                    
How the ISPAD guidelines are adhered to varies among different hospitals in different parts of the 
world. Guidelines give however, objective criteria for registering which again can, via benchmarking 
and increased awareness, improve diabetes care for children internationally. 
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Introduction 
Diabetes Mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting 
from defects in insulin secretion, insulin action, or both (1). DM is classified into different types. Type 
1 diabetes (T1D) is characterized by β-cell destruction, usually leading to absolute insulin deficiency. 
Type 2 diabetes (T2D) is a result of insulin resistance in peripheral tissue. It ranges from relative 
insulin deficiency because of predominantly insulin resistance to a predominantly defect of insulin 
secretion with or without insulin resistance. Maturity Onset Diabetes of the Young (MODY) and 
secondary diabetes, are examples of other less common forms of DM in children. Patient with T1D 
will die without insulin treatment (2, 3). In contrast, patients with T2D can remain undiagnosed for 
many years (4). Poorly managed diabetes might lead to serious complications affecting the heart and 
blood vessels, eyes, kidneys and nerves (2) and early death.  Normalized blood glucose (BG) levels, 
blood pressure and cholesterol can help delay or prevent diabetes complications. Regular controls 
and monitoring for complications and risk factors are needed (5, 6). 
DM is one of the most common non-communicable diseases globally. In 2011 there were 366 million 
adults between 20-79 years who had diabetes according to the International Diabetes Federation 
(IDF) (7). IDF also estimated DM to be the cause of as many as 4,6 million deaths in 2011 (8). Among 
children, T1D has the highest incidence of the different types of DM, with Finland and Sardinia 
reported to have the highest incidence and China and Venezuela the lowest (9). The increase is 
highest among the youngest children, especially in the European population. The number of children 
developing this form of diabetes every year has increased rapidly all over the world, except in Central 
America and West Indies where the trend is decreasing (9, 10).  However, latest research regarding 
incidence of T1D for children in Finland highlighted two significant changes in the trends between 
1980 and 2011. The research showed an annually increase until 2005, followed by a plateau until the 
end of 2011 (11). Also Sweden has reported a similar plateau in incidence from 2005-2007 (12) and 
Norway from 2004-2012 (13). 
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Despite the fact that insulin treatment is lifesaving, even today, almost a century after the discovery 
of insulin, the most common cause of death in a child with diabetes, in a global perspective, is lack of 
access to insulin. Many children also die before their diabetes is diagnosed (14, 15). The lack of 
access to insulin in parts of the world is not only due to insulin availability and cost.  Also the 
availability of supplies to administer insulin play a role (16) . Proper diabetes care; trained personnel, 
diagnostic and monitoring facilities are necessary to improve prognosis. This care is not sufficient in 
all countries (17). 
Over the world, several organizations such as the World Health Organization (WHO), the American 
Diabetes Association (ADA), the Canadian Diabetes Association (CDA) and others have developed 
guidelines to ensure optimized diabetes management. In 1995, the International Society for Pediatric 
and Adolescent Diabetes (ISPAD) developed the first set of international guidelines for management 
of T1D among children and adolescent. The current guidelines (2011) have been developed by ISPAD 
and the IDF. While there is extensive evidence on the optimal management of T1D, unfortunately 
such care is not reaching all people who could benefit. Guidelines are one part of a process which 
seeks to address those problems (18). 
Aims 
The aim of this study was to explore if international guidelines describing diabetes care for children 
are followed in various parts of the world. If they are not followed, we wanted to find out why and 
how practice is different from the international recommendations. Hopefully this study can 
contribute to exchange of knowledge about diabetes care and increase awareness about diabetes in 
children.  
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Material and methods 
During the spring of 2009 medical students from the University of Oslo, together with Professor 
Borghild Roald MD PhD and Senior Consultant Torild Skrivarhaug MD PhD, made a questionnaire 
based on the 2009 ISPAD guidelines. The questionnaire was designed to collect information about 
T1D in children less than 15 years of age. The questionnaire was composed of two parts. Part one 
was designed to map the conditions within a country concerning incidence, prevalence, mortality, 
national health, patient diabetes organizations and diabetes registers. Part two focused on specific 
hospitals concerning diabetes care in children; hospitalization, diagnostics, treatment and follow up, 
treatment goals, quality of life and mental health. As part of their compulsory student thesis, 
students visited 16 different hospitals in eight countries between 2009 and 2011. At the different 
hospitals diabetes care in children was observed. The daily routines and work was taken part in, and 
personnel working with children with diabetes were interviewed semi-structurally using the 
questionnaire. The questionnaire was translated to English before departure and again translated to 
Spanish with the help of Dr. Adriana Rousaus, specialist in diabetes and nutrition, at Hospital de 
Niῆos in Buenos Aires, Argentina. The questionnaire was sent to the interview subject via e-mail prior 
to the meeting. The interviews were tape recorded and transcribed shortly after the conversations 
had taken place. Part two of the questionnaire was answered by the interviews. Part one was 
answered mainly through search in literature and on the internet. The information gathered from the 
interviews contained no sensitive patient data.  When the work with comparing data from the 
different countries started, an e-mail was also sent to the contact person at KEM (India) to collect 
missing data for the comparative study to be as complete as possible.  
Oslo University Hospital (OUH) consists of what used to be four different hospitals in the city of Oslo. 
OUH includes Ullevål University Hospital (UUH), which was a single unit before the merge in 2009. 
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The medical students Anja Kwetzinsky and Heidi Lehmann visited Hospital de Niῆos in Buenos Aires 
and Hospital Narciso Lopes south of Buenos Aires in Argentina in January 2011. They also visited 
Buskerud Central Hospital (BCH) in Drammen, Norway, in December 2010. 
Lene Sleire visited University Teaching Hospital of Butare (UTHB), Rwanda, in 2011 and UUH, Norway, 
in 2009. 
Martine Aurora Munkvold visited OUH in 2009 prior to her departure to Australia. There she visited 
The Royal Children’s Hospital (RCH) in Melbourne, Victoria, and Alice Springs Hospital (ASH) in Alice 
Springs, Northern Territory, in the autumn 2009. She visited John Hunter Hospital (JHH) in Newcastle, 
New South Wales, in 2010. 
Eirin Eilertsen and Natalie Lie Berntsen visited The British Columbia Children’s Hospital (BCCH), 
Vancouver, British Columbia, and The Hospital for Sick Children (SickKids), Toronto, Ontario in 
Canada during the summer of 2010. They also visited OUH in 2010. 
Lise Haldorsen Willumsen and Idun Stenhammer Aanerød visited Children’s Hospital of Orange 
County (CHOC), California, and University of Minnesota Amplatz Children’s Hospital (U of M), 
Minnesota, both in the United States of America in 2009. In addition they visited UUH, also in 2009. 
Celine Urdal visited Tygerberg Hospital (TH), Western Cape, South Africa in January 2010 and 
Stavanger University Hospital (SUH), Norway, in December 2011. 
Vigdis Skinnemoen Ottersen and Sigrid Børte visited King Edward Memorial Hospital (KEM) in Pune, 
Maharastra, India in 2010 and Elverum Hospital, Norway. 
Our literature review derives from a non-systematic search in PubMed and from the ISPAD 
guidelines’ references.  
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Table 1: Hospital addresses and number of subjects in out trial  
Hospital name Address 
Number of 
children followed 
up 
India, King Edward Memorial Hospital 
489 Rasta Peth, Sardar Moodliar Road,          Pune 
-411011 275 
Norway, OUS/UUH Kirkeveien 166, 0450 Oslo 303 
Norway, SUH 
Gerd-Ragna Bloch Thorsens gate 8,                 
4011 Stavanger  170 
NOR, Buskerud Central Hospital Dronninggata 28, 3004 Drammen 130 
Norway, Elverum Furnesvegen 26, 2380 Brumunddal 113 
USA, Children's Hospital of Orange County 1201 W La Veta Ave, Orange, CA 1100 
USA, University of Minnesota Amplatz Children's 
Hospital 2450 Riverside Ave, Minneapolis, MN 55454 250 
Canada, British Columbia Children's Hospital 4480 Oak Street, Vancouver BC V6H 3N1 1023 
Canada, Hospital for Sick Children 555 University Avenue, Toronto, Ontario 1000 
Argentina, Hospital Narciso Lopez O´Higgins - 1333, Buenos Aires 26 
Argentina, Hospital de Niῆos Granada 4175 San Justo, 1754, Buenos Aires 600 
Rwanda, University teaching hospital of Butare Huye District, Butare Town Data not available 
South Africa, Tygerberg Hospital Francie van Zijl Avenue, Tygerberg, 7505 137 
Australia, The Royal Children´s Hospital in 
Melbourne 50 Flemington Road, Parkville Victoria 3052 1700 
Australia, Alice Springs Hospital Gap Rd, Alice Springs NT 0870 8 
Australia, John Hunter Hospital, Newcastle 2 Lookout Rd, New Lambton Heights NSW 2305 363 
 
Total: 7198 
 
At KEM (India), 829 children with T1D were registered, but 250-300 children were reported to attend 
regular follow-ups.
 13 
 
Our data could not be collected without the help from our informants at the visited hospitals.  
Table 2: Informants at the hospitals visited 
Hospital Informants and contact persons 
King Edward Memorial Hospital 
Professor Chittaranjan Yajnik MD 
Sonali (unknown profession) 
University Teaching Hospital of Butare  Professor J.W.O. Iraka 
Tygerberg Hospital 
MD Ekkekard Zöllner 
Diabetes nurse Fiona Liebeuberg, RN 
Hospital Narciso Lopez MD Lidia Caracotche 
Hospital de Niῆos 
MD Adriana Rousaus 
MD Liliana Trifone 
 
The Royal Children´s Hospital in Melbourne 
Professor George Werther MD 
Professor Fergus Cameron MD 
Diabetes educator nurse Andrew Boucher, RN 
 
Alice Springs Hospital 
MD Rose Fahy  
Diabetes educator Glynis Dent 
John Hunter Hospital Professor Patricia Crook 
The British Columbia Children’s Hospital MD Daniel Metzger 
The Hospital for Sick Children  
MD Denis Daneman  
Different members of the diabetes team 
Children’s Hospital of Orange County  MD Mark Daniels 
 
University of Minnesota Amplatz Children’s Hospital  
Professor Antoinette Moran MD  
Diabetes educator nurse Shannon Beasley, RN 
Diabetes educator Anne E Jackson 
Ullevål University Hospital (Oslo University Hospital) 
Diabetes nurse Siv Janne Kummersnes, RN 
MD Torild Skrivarhaug, PhD 
Buskerud Central Hospital 
Diabetes nurse Åse Løkkeberg Figenschau, RN 
Diabetes nurse Helene Wang, RN 
Stavanger University Hospital  Diabetes nurse Liv Haram, RN 
Innlandet Hospital Elverum 
Head of the pediatric department Jon Grøtta, MD 
Diabetes nurse Tove Berg, RN 
 
Data from Norwegian hospitals have also been provided by the Norwegian Childhood Diabetes 
Registry (NCDR). NCDR was established in 2006. Registration is voluntary. Children and/or parents 
have to give their written consent at diagnosis. When the patient turns 18 years old, he or she must 
give their consent again. Since 2008, all hospitals in Norway have participated in the registration. In 
2011, 2568 children were in the register. That equals 95% of children with diabetes treated in 
pediatric departments in Norway. One of NDCR’s main tasks is to analyze and report back results to 
the hospitals participating in the register. All the pediatric departments are benchmarked on results 
and screening procedures. The aim is to promote quality of the care for children and adolescent with 
T1D in Norway.   
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Part 1: Literature review on diabetes mellitus in children and 
adolescents 
Type 1 Diabetes 
Epidemiology for type 1 diabetes 
T1D is one of the most common endocrine and metabolic conditions in childhood. The total child 
population of the world (0-14 years) was in 2010 1, 9 billion. Approximately 480 000 children have 
T1D, which equates to 0.02%. 76 000 new cases are diagnosed every year. This reflects an annual 
incidence of 3% (10).  Two international collaborative projects, the Diabetes Mondiale study 
(DiaMond) (9) and the Europe and Diabetes study (EURODIAB) (19) have monitored trends in 
incidence. The incidence of T1D has increased all over the world (9), but it seems that the increase 
has been strongest in low incidence countries (20). The encouraging observation in some recent 
studies is that the incidence of childhood T1D in some countries has ceased to increase after a period 
of accelerated increase (11-13). Even though T1D is diagnosed in all age groups, it seems that the 
incidence increases with age until puberty (10-14 years) (9). The incidence of T1D among children 
under the age of 14 years varies greatly between countries and between different ethnic populations 
within countries (9). Finland has the highest recorded incidence in children < 15 years of 64.9 per 
100 000 person-years (in 2006) (11). China has among the lowest incidences between 0.1 and 4.5 per 
100 000 person-years (in 1990-1996). Norway, Canada, the USA and Australia are high incidence 
countries, while Argentina is intermediate incidence and India and countries in Sub-Saharan Africa 
are low incidence countries (9).  
Etiology and pathogenesis for type 1 diabetes 
The characteristic feature of T1D is the selective destruction of the insulin producing β-cells of the 
pancreas. This leads eventually to complete insulin deficiency. The etiology is not completely 
understood, but serological markers are present in 85-90% of individuals when hyperglycemia is 
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detected (1, 21). These markers include islet cell antibodies, GAD, IA-2, IA-2β and insulin 
autoantibodies. Susceptibility to autoimmune T1D is determined by multiple genes, human leukocyte 
antigen (HLA) genes having the strongest known association. The environmental triggers (chemical 
and/or viral) which initiate pancreatic beta cell destruction remain largely unknown, but the process 
usually begins months to years before the manifestation of clinical symptoms (1). T1D becomes 
clinically symptomatic when approximately 90% of pancreatic β-cells are destroyed (22).  
 
Type 2 Diabetes 
T2D is a growing disease among children and adolescents. It used to be a disease among the middle-
aged and older generation, but in the latest decade more young people have been affected.  Obese 
children and adolescents with newly onset T1D can be misdiagnosed having T2D (23). Both genetics 
and lifestyle are factors that are involved in the pathogenesis of T2D. A positive family history of T2D 
gives a two to fourfold increased risk to develop T2D, and 15% to 25% of first-degree relatives of 
persons with T2D develop impaired glucose tolerance (IGT) or diabetes (24). Obesity and lack of 
physical activity is also a big contribution to the increased incidence of T2D in the world (25).  
T2D is a condition which results in both hyperglycemia and hyperinsulinemia. This is due to insulin 
resistance in peripheral tissue, reduced ability to glucose transport over the cell membranes, 
increased glucose production by the liver and deranged insulin secretion by the pancreatic beta cells.  
Over time, usually a few years, the pancreatic beta cells will be exhausted and fail to produce insulin 
(25, 26).   
Treatment for T2D depends on the symptoms, severity of the hyperglycemia and whether ketosis is 
present or not. To control BG levels it may be sufficient to make a lifestyle change with weight- loss 
through physical activity and dietary management.  Along with normalization of the BG it is 
important to control co-morbidities, such as hypertension, dyslipidemia, nephropathy, retinopathy 
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and hepatic steatosis. If control of BG is not achieved by lifestyle change alone, pharmaceutical 
therapy such as oral tablets to increase insulin sensibility must be added. Failure of treatment after 
three months with oral tablets, indicate the need to start insulin therapy for T2D patients (23).  
 
Diagnostic criteria 
ISPAD diagnostic criteria for T1D are based on both BG measurements and the presence of 
symptoms. Presenting symptoms of diabetes in children are usually polyuria, polydipsia, weight loss 
and blurring of vision in association with glycosuria and ketonuria. Four ways to diagnose diabetes 
are possible (1, 27): 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 11.1 mmol/l (200mg/dl). 
Casual is defined as any time of day without regard to time since last meal.  
or 
2. Fasting plasma glucose ≥ 7.0 mmol/l (≥ 126 md/dl). Fasting is defined as no caloric intake for 
at least 8 hours.  
or 
3. 2 hour post load glucose ≥ 11.1 mmol/l (≥ 200 mg/dl) during an oral glucose tolerance test 
(OGTT). The test should be performed as described by WHO (28), using a glucose load 
containing the equivalent of 75g anhydrous glucose dissolved in water or 1.75 g/kg body 
weight to a maximum of 75g.   
or 
4. Glycosylated hemoglobin (HbA1c) ≥ 6.5% (Presented in the 2011 ISPAD guidelines). 
 
ADA and CDA have similar diagnostic criteria for T1D (29, 30). 
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Treatment 
Children and adolescents with T1D require lifelong insulin substitution from the time of diagnosis. 
Before the discovery of insulin in 1921, few patients with T1D survived more than a year or two 
because of the acute effects of the disease (31). The aim with insulin treatment is to replace the 
missing physiological insulin and have as close to normal glycemic control as possible.  Since insulin is 
destroyed in the gastrointestinal tract it must be given as injections, either subcutaneously or 
intravenously. Several insulin formulations and regimes are available. The choice depends on the 
resources available and the children and their families preferences. It is important to optimize 
compliance to prevent the imbalance between hypo- and hyperglycemia which results in the acute 
and late complications of the disease (32, 33).  
Three different types of insulin may be used. They are classified by their onset, peak and duration of 
action: 
 Rapid-acting and short-acting types.  
o Usually given before meals as a bolus based on the BG level and the carbohydrate 
content of the food.  
o When delivered by continuous subcutaneous infusion via an insulin pump they 
provide a basal insulin level. 
 Intermediate-acting type: 
o Usually given two or three times a day.  
o Can also be given in combination with long-acting insulin. 
 Long-acting type: 
o Usually given once or twice a day. 
o Provides a basal insulin level in the fasting state that suppresses glucose production 
by the liver and maintains a glucose level near normal. 
Insulin can be administered through syringes, pen or insulin pump.  
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Different insulin regimens are available for adolescents and children. ISPAD recommends at least two 
injections of insulin a day and that all children should have available rapid – acting or regular insulin 
for crisis management (33). 
 Conventional regimen: 
o “Two injections daily” or “three injections daily” regimen. 
o Administration of an intermediate-acting insulin at least twice a day, at breakfast and 
either at dinner or bedtime, combined with at two or three times a day injection of 
rapid – or short- acting insulin also at breakfast or dinner, sometimes at lunch or 
bedtime depending on the BG concentrations (32, 33). 
o This traditionally regimen is fixed. The children and their family have to live after a 
planned schedule and adjust meals and physical activity to fit this regimen. 
 Intensive regimen, the basal bolus concept, multiple injection therapy (MIT): 
o Multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). 
o The aim with this regimen is to imitate normal physiologic insulin secretion by 
providing a basal insulin level through the day with bolus of rapid-or short acting 
insulin before meals and snack to prevent postprandial elevation of BG. 
o The bolus is based on the carbohydrate content of the meal, physical activity level 
after the meal and current BG level. 
o  This gives more flexibility than a conventional regimen, but depends on a stricter 
commitment from the children and their family with increased BG monitoring, 
carbohydrate counting, judging the impact of exercise on insulin requirements and 
increased frequency of insulin administration to obtain the benefits. 
o MDI can require six to seven injections daily, and therefore insulin pump (CSII) is 
often preferred (32).   
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The Diabetes Control and Complications Trial (DCCT) compared the intensive regimen with the 
conventional regimen through a randomized clinical trial over a mean period of 6.5 years, with 
regard to their effect on the microvascular and macrovascular complications of T1D. Results of the 
trial showed that intensive therapy effectively delays the onset and slows the progression of 
retinopathy, nephropathy and neuropathy in patients with T1D (5). 
Insulin treatment is lifesaving for children and adolescents with T1D, but to achieve optimal effect 
and prevent long term complication a comprehensive diabetes management must be followed. This 
includes education, nutritional management, physical activity, rules for sick days and psychosocial 
support (33).  There are large differences in the diabetes management all over the world. In some 
countries this is free, including self-care tools and insulin, but in others the patients must pay 40-60% 
of the health care expenditures themselves (10, 34).   
 
Treatment target 
Self blood glucose monitoring (SBGM) is an important tool to better daily glycemic control and reach 
treatment target for T1D patients. SBGM gives immediate information about the BG level, depending 
on this the patients and their caregivers can immediately adjust insulin injections to optimal treat.  
Frequency of SBGM correlates with glycemic control and should be performed four to six times a day.  
BG targets with the goal of achieving as normal as possible BG (3.6-5.8 mmol/L) and avoiding severe 
hypoglycemia and also mild to moderate hypoglycemia, is individually determined for each child (35). 
HbA1c is used as a long-term monitor for glycemic control and late complications (5). HbA1C is 
hemoglobin to which glucose is attached. Through the lifecycle of the red blood cell of approximately 
120 days glucose get irreversible bound to the hemoglobin, and HbA1C can therefore be used as an 
indicator for the average BG level over the past three months (35).  
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DCCT and other studies have shown that through better glycemic control measured with a low 
HbA1c the patients will get fewer or delayed microvascular complications. Based on this ISPAD 
recommend the target HbA1C for age-groups up to 18 years to be < 7.5% (5, 35).  
ADA and CDA recommends considering age when calculating glycemic goals for children and 
adolescents with T1D to prevent the increased risk of hypoglycemia associated with lower HbA1C.  
 
Table 3: American Diabetes Association recommendations for target glycosylated hemoglobin 
(HbA1c) for children and adolescents with type 1 diabetes (36) 
Age 
(years) 
HbA1c 
(%) 
Rationale 
< 6 < 8.5 
 Caution regarding vulnerability to hypoglycemia and insulin sensibility. 
 May be unpredictable in dietary intake and physical activity. 
 Reasonable with a lower target (< 8.0%) if achieved without excessive hypoglycemia. 
6-12 < 8  
 Caution regarding vulnerability to hypoglycemia. 
 Reasonable with a lower target (< 7.5%) if achieved without excessive hypoglycemia. 
13-19 < 7.5   Reasonable with a lower target (< 7.0%) if achieved without excessive hypoglycemia. 
 
 
Table 4: Canadian Diabetes Association recommendations for target glycosylated hemoglobin 
(HbA1c) for children and adolescents with type 1 diabetes (37, 38)  
Age 
(years) 
HbA1c (%) 
2013 
HbA1c (%) 
2008 
Considerations 
< 6 < 8.0* < 8.5 Caution is required to minimize hypoglycemia because of the potential association 
between severe hypoglycemia and later cognitive impairment. 
6-12 ≤ 7.5** ≤ 8.0 Targets should be graduated to the child's age 
13-18 ≤ 7.0 ≤ 7.5 Appropriate for most adolescents. 
* Consider target of < 8.5% if excessive hypoglycemia occurs. 
 ** Consider target of < 8.0% if excessive hypoglycemia occurs. 
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Complications 
Acute complications 
Patients with T1D on insulin treatment can experience that the BG can become either too high or too 
low. If too much insulin is given the patient becomes hypoglycemic and can eventually become 
unconscious with or without convulsions. With total or relative lack of insulin the patient can become 
hyperglycemic and reach a state of diabetic ketoacidosis (DKA). Both conditions are associated with 
both short term (39) and serious life -threatening challenges (40).  
 
Table 5: The biochemical criteria for diabetic ketoacidosis used by ISPAD*and ADA** (41): 
 
 
ISPAD* ADA** 
Hyperglycemia Blood glucose > 11 mmol/L (≈200 mg/dl) Blood glucose: >14 mmol/L (> 250 mg/dl) 
Venous pH < 7.3 < 7.3 
Bicarbonate < 15 mmol/L - 
Ketones Ketonemia and ketonuria Ketonemia and ketonuria 
*International Society for Pediatric and Adolescent Diabetes **American Diabetes Association  
 
Australian Pediatric Endocrine Group (APEG) follow the criteria stated by ISPAD(42). CDA 
acknowledges the same characteristics and biochemical values as ISPAD and ADA(30).  
Late complications 
After the introduction of insulin in treatment, diabetes is no longer an acute threat to life. It is still 
associated with increased morbidity and mortality of other reasons, especially after many years of 
disease. Elevated plasma glucose predisposes to micro- and macrovascular complications such as 
retinopathy, nephropathy, neuropathy, angiopathy and myocardial- and cerebrovascular insults. 
Intensive diabetes treatment, with as close to normal as possible BG, decreases the incidence of 
microvascular- (5) and macrovascular complications (43). Screening for late complications is 
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important in patients with T1D because the microvascular complications have early, asymptomatic 
and reversible stages before the end stage damages (5, 44).  
 
Table 6: ISPAD* recommendations from 2009 concerning screening for microvascular complications 
in children with type 1 diabetes (45) 
 
 When to commence screening Screening methods 
Retinopathy 
 
Annually from age 11 years with 2 years diabetes duration 
and from 9 years with 5 years diabetes duration 
Fundal photography or mydriatic 
ophthalmoscopy (less sensitive) 
Nephropathy 
 
Annually from age 11 years with 2 years diabetes duration 
and from 9 years with 5 years diabetes duration 
Urinary albumin/creatinine ratio or first 
morning albumin concentration 
 
Neuropathy 
 
Unclear History and physical examination 
*International Society for Pediatric and Adolescent Diabetes 
 
The ISPAD/IDF guidelines from 2011 recommend that peripheral and autonomic neuropathy should 
be assessed by history and physical examination from age 11 years with two years diabetes duration.  
Diabetic retinopathy (DR) presents as non-proliferative DR which is the first reversible stage of eye 
affection from DM. It will, without intervention, progress to proliferative diabetes retinopathy (PDR) 
which is an irreversible threat to vision. The severity of DR is related to higher levels of HbA1c (46). 
When DR has progressed to PDR, laser treatment called photocoagulation has a good chance of 
reducing further vision loss (47). If discovered in the phase of microalbuminuria; tougher treatment 
for hypertension, hyperglycemia and the microalbuminuria itself can prevent or delay progression to 
end stage renal failure (48, 49).  
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Table 7: Definition of diabetic nephropathy (50)   
 
 
Definition 
 
Microalbuminuria* 
Albumin excretion rate (AER) between 20 and 200 μg/min or AER 30 – 300 mg/24 h in 24-h urine 
collections 
or 
Albumin concentration (AC) 30 – 300 mg/L (on early morning urine sample) 
or 
Albumin/creatinine ratio (ACR) 2.5 – 25 mg/mmol or 30 – 300 mg/gm (spot urine) in males and 3.5 – 
25 mg/mmol in females (because of lower creatinine excretion) 
 
Proteinuria* 
Persistent proteinuria greater than 500 mg/24 hours or albuminuria greater than 300 mg/24 hours 
or 
Albumin concentration (AC) > 300 mg/L 
or 
Albumin/ creatinine ratio (ACR) > 25 mg/mmol 
*In two out of three consecutive urine samples 
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Part 2: Diabetes in a global perspective 
WHO have listed diabetes along with other non-communicable diseases such as; cancer, 
cardiovascular diseases and chronic respiratory diseases as the leading cause of mortality in the 
world (51). Diabetes is a chronic disease that gives a social and economic burden to the affected 
individuals and their families (10).  
 
Population and economy 
Our study compares data from eight countries which all is different in social and economic 
development.  Gross domestic product (GDP) per capita can be used as an indicator for the country’s 
standard of living. The World Bank’s definition of GDP is: “the sum of gross value added by all 
resident producers in the economy plus any product taxes and minus any subsidies not included in 
the value of the products. It is calculated without making deductions for depreciation of fabricated or 
for depletion and degradation of natural resources”. GDP per capita is GDP divided with midyear 
population in the country. Norway is one of the world’s richest country with a GDP per capita of 100 
US$ and a population just over 5 million people in 2012. India, on the other hand, had a population 
counting 1.2 billion people and a GDP per capita on 1.5 US$ in 2012. Four of the countries in this 
study; Norway, Australia, Canada and the USA are defined as high income countries with a GDP per 
capita ranging from 50 to 100 US$. The other four countries; Argentina, South Africa, India and 
Rwanda are defined as middle- and low- income countries with GPD per capita from almost 0.6 to 
11.5 US$ (52). 
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Table 8: Population and gross domestic product in 2012 in studied countries  
Country Population
 (*) 
Overall proportions of ethnicities
(**) 
Gross domestic 
product (GDP) per 
capita (current US$ 
05.09.13)
 (*) 
Gross domestic 
product (GDP)
 
(Current US$ per 
05.09.13), in 10
9
, 
billion
 (*) 
Norway 5,018,869 
Norwegian 94.4% (includes Sami, about 
60,000), other European 3.6%, other 2% 
(2007 estimate) 
99.6 499 
Argentina 41,086,927 
White (mostly Spanish and Italian) 97%, 
mestizo (mixed white and Amerindian 
ancestry), Amerindian, or other non-white 
groups 3% 
11.6 475 
Australia 22,683,600 
White 92%, Asian 7%, aboriginal and other 
1% 67 1520 
Canada 34,880,491 
British Isles origin 28%, French origin 23%, 
other European 15%, Amerindian 2%, other, 
mostly Asian, African, Arab 6%, mixed 
background 26% 
52 1821 
India 1,236,686,732 
Indo-Aryan 72%, Dravidian 25%, Mongoloid 
and other 3% (2000) 1.5 1841 
Rwanda 11,457,801 
Hutu (Bantu) 84%, Tutsi (Hamitic) 15%, Twa 
(Pygmy) 1% 0.6 7 
South-Africa 51,189,306 
Black African 79%, white 9.6%, colored 
8.9%, Indian/Asian 2.5% (2001 census) 7.5 384 
USA 313,914,040 
White 79.96%, black 12.85%, Asian 4.43%, 
Amerindian and Alaska native 0.97%, native 
Hawaiian and other Pacific islander 0.18%, 
two or more races 1.61% (July 2007 
estimate)
5 
50 15684 
(*) 
Numbers from The World Bank(53)  
(**) 
The  World Factbook, Central Intelligence Agency (54) 
5
A
 
 separate list ing for  Hispanic is not included because 
the US Census Bureau considers Hispanic to mean persons of Spanish/Hispanic/Latino orig in including 
those of Mexican, Cuban, Puerto Rican, Dominican Republic,  Spanish, and Central or South American 
origin l iving in the US who may be of  any race or  ethnic group (white, black, Asian, etc.) ;  about 15.1% 
of the total  US population is Hispanic  
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Health economy 
All the member states of WHO made in 2005 a commitment to work for universal health coverage. 
They believed that all people should have access to the health services they needed without the risk 
of impoverishment and financial ruin. WHO stated that working towards universal health coverage is 
a powerful mechanism for achieving better health and well-being, and for promoting human 
development (55).  In the USA, the GDP was calculated to be approximately 15500 billion US$ in 
2012. Their total expenditure on health was approximately 18% of their GDP in 2011. The same year, 
46% out of total expenditure on health was general governmental expenditure. Along with India and 
South Africa, the USA is one of the countries in our study where the health expenditures are less 
financed by the general governmental expenditures. India’s GDP was approximately 1800 billion US$ 
in 2012. In 2011 they used 4% of their GDP on health expenditures, and out of the total expenditure 
on health, 31% was general governmental financed.  South Africa’s GDP in 2012 was approximately 
384 billion US$. Total expenditures on health in this country were 8.5% of GDP in 2011. Out of their 
total expenditure on health in 2011, 48% was general governmental expenditures. In our study, the 
countries where most of the total expenditure of health is financed from the general government 
expenditures are Norway, Canada, Australia and Argentina. Their general governmental expenditure 
was respectively 86%, 70%, 66% and 61% of the total expenditure on health in 2011. 
 
Table 9: Health economics in 2011 in studied countries (*) 
Country 
Total expenditure on 
health as a % of the GDP
 
General government expenditure on health 
as % of total expenditure on health
 
General government expenditure on health 
as % of total government expenditure
 
Norway 9 86 18 
Argentina 8 61 20 
Australia 9 69 17 
Canada 11 70 18 
India 4 31 8 
Rwanda 11 57 24 
South-Africa 8.5 48 13 
USA 18 46 20 
(*)
 Numbers from the World Health Organization (56) 
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Mortality and average life expectancy  
Infant mortality -, child mortality- and life expectancy rates also reflect the degree of development in 
a certain country.  Infant mortality rate is the number of infants dying before reaching one year of 
age, per 1000 live births in a given year. India, estimated with 47 deaths/ 1000 live births in 2011, 
had the highest infant mortality among the countries in our study that year. Norway is on the other 
side of the scale with 3 deaths/1000 live births. Child mortality rate is the number of children who die 
before the age of five, per 1000 live births per year. In 2011 in India, the child mortality rate was 61 
deaths/ 1000 live births. The child mortality rate in Norway the same year was 3 deaths/ 1000 live 
births. Estimated life-expectancy rate in 2011 was calculated to be 67 years for women and 64 years 
for men in India. In Norway, the rate was estimated to be 84 for women and 79 for men the same 
year. 
 In 2011, Australia, Canada and the USA also had low infant mortality, like Norway. Their infant 
mortality rate was 4, 5 and 6 deaths/1000 live births respectively. Rwanda and South Africa with 38 
and 35 deaths/ 1000 live births had lower infant mortality rate then India, but it is still defined as 
high, and is much higher than the other countries in our study. The infant mortality rate in Argentina 
was 13 deaths / 1000 live births in 2011.  
The child mortality rate follows the same trend as the infant mortality rate among the countries in 
our study in 2011. Australia, Canada and the USA had a child mortality rate at 5, 6 and 7 deaths/ 
1000 live births respectively. In Rwanda and South Africa the rate was 54 and 47 deaths/ 1000 live 
births. The child mortality rate in Argentina was 14 deaths/ 1000 live births. 
The country with the highest life expectancy rate in 2011 was Australia with 84 years for women and 
80 years for men. Australia was followed by Norway, Canada, the USA and Argentina. The life 
expectancy rate in these countries varied from 80 – 84 years for women and 72 – 79 for men. The 
country with the lowest life expectancy rate in 2011 was South Africa with 53 for women and 52 
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men. Along with South Africa, Rwanda and India was the countries with the lowest life expectancy in 
2011.  
 
Table 10: Average life expectancy and mortality in 2011 in studied countries (*) 
 
Country 
Average life 
expectancy for 
women, (years)
 
Average life 
expectancy for men, 
(years)
 
Infant mortality 
deaths/ 1,000 live 
births
 
Child mortality deaths under 5 
years/ 1,000 live births
 
Norway 84 79 2.6 3.1 
Argentina 80 72 12.6 14.1 
Australia 84 80 4.1 4.5 
Canada 83 79 4.9 5.6 
India 67 64 47.2 61.3 
Rwanda 57 54 38.1 54.1 
South-Africa 53 52 34.6 46.7 
USA 81 76 6.4 7.5 
(*) 
Numbers from the World Bank (57) 
 
 
National health 
WHO follows the situation and trends on the world’s health workforce. In The World State Report 
2006 – “Working together for health”, they stated that there are an unevenly distribution of health 
workers across the globe. The smallest health workforce is in the countries with the highest burden 
of disease, while the countries with less needs have the highest numbers of health workers. Less 
than 1% of the world’s financial resources are in the African region and they suffer from more than 
24% of the global burden of disease. Nevertheless, this region only has 3% of the world’s health 
workforce (58). Table 11 shows the physician density per 1000 population in the countries in our 
study. Norway, Argentina, Australia, Canada and the USA had the highest density. India and the Sub–
Saharan countries, Rwanda and South Africa, had the lowest density of physicians.  
The national health systems are different in all the eight countries studied. Medical expenditures for 
individuals with diabetes are two to three times more than for those without diabetes (59).  Several 
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studies have shown that the disease presents a high burden, not only for the individuals, but also for 
the society. This is due to costs caused by loss of productivity from disability and premature mortality 
(34, 60, 61).  Some of the countries had a health system that finances all or parts of treatment 
necessary for children and adolescents with T1D. Table 11 gives an overview of the financial support 
an individual with diabetes could get in the countries in our study.  
 
Table 11: Physician density and national health support systems for diabetes in studied countries 
 
 
Country 
Physicians 
density 
(physicians/
1,000 
population)
1 
in 2006 
Are there any 
support system that 
finance the costs 
associated with 
diabetes medication 
and equipment? 
If there are 
any support 
systems; 
which 
medication is 
financed? 
If there are any support systems; 
which materials is financed? 
If there are any support 
systems; does the patient 
have to pay anything? If so, 
how much % 
Norway  3.13 
Yes. All citizens are 
member of the 
Norwegian Health 
Insurance. This gives 
all citizens equal 
right to help 
services
2
. 
Insulin
2 
antidiabetic 
drugs and 
glucagon.
 
Syringes, needles, insulin pen, 
insulin pump, materials for the 
insulin pumps, home BG meters, BG 
test strips, finger-pricking devices, 
lancets for finger-pricking, SBGM 
devices, urine sticks
2
. 
It is a deductible on health 
supplies and support on 
1980 nok (ca 330 USD) per 
year. When reached this 
amount health support and 
supplies is free of charge
2
. 
Argentina  3.01 
Yes, public health 
services are free for 
all individuals 
making use of them 
regardless of health 
insurance
3
. 
Insulin
4
. 
Pharmaceutical industry provides BG 
meter and strips to measure BG x3 
per day
5
.
 
No data available. 
Australia 2.47 
Yes, if registered in 
the National 
Diabetes Service 
Scheme (NDSS)
5
 or 
having a Health Care 
Card
6
. 
Health care 
card and 
Pharmaceutical 
Benefits 
Scheme gives 
cheaper 
prescription 
medicine
6
. 
Subsidized testing strips for checking 
BG levels, free insulin syringes and 
pen-needles (if require insulin or 
non-insulin inject able BG lowering 
medications), information services 
on managing life with diabetes 
subsidized insulin pump 
consumables (IPCs)
5
. 
No data available. 
Canada 2.14 
Yes, but data for 
criteria not available. 
Insulin. No data available. No data available. 
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Table 11: Physician density and national health support systems for diabetes in studied countries 
 
 
Country 
Physicians 
density 
(physicians/
1,000 
population)
1 
in 2006 
Are there any 
support system that 
finance the costs 
associated with 
diabetes medication 
and equipment? 
If there are any 
support systems; 
which 
medication is 
financed? 
If there are any support systems; 
which materials is financed? 
If there are any support 
systems; does the patient 
have to pay anything? If so, 
how much % 
India 0.60 
Yes, philanthropic: 
Individual donations, 
Pharmacy 
companies, non-
governmental 
organizations. The 
support is for 
selected patients 
depending on age, 
socio-economic 
status etc
7
. 
 
Insulin
7
. 
Glucometers, stripes, injection 
devices (pens, syringes), patient 
education material, demo kits, 
material for different recreational 
activities and events
7
. 
Yes, majority of the times, 
partly. (Up to 50%)
7
. 
Rwanda 0.05 No. 
Some private 
organizations 
provide free 
insulin. Patients 
still has to pay 
the OPC 
registration fee 
of 1 EUR once a 
month to get the 
insulin 
prescription. 
No data available. No data available. 
South –
Africa 
0.77 Yes
8
. 
Insulin, 
antidiabetic 
drugs and 
glucagon
8
. 
Syringes, needles, insulin pen, 
home BG meters, BG test strips, 
finger-pricking devices, lancets for 
finger-pricking and urine sticks to 
check for ketonuria
8
. 
Child <5 years: parents do 
not need to pay anything for 
the medication and the 
equipment. >5 years: 
parents have to pay. How 
much depends on they 
having a job or not and the 
income
8
. 
USA 2.56 No data available. 
No data 
available. 
No data available. No data available. 
1
The World Health Report 2005, WHO(62).
2
The Norwegian Diabetes Association(63)
3
UN Refugee Agency(64). Public 
hospitals provide care to the poor with or without insurance, subsidizes obras socials and occasionally those with high 
income and private insurance who preferred a particular institution or personnel(65).
4
Personal communication with Dr. 
Lidia Caracotche.
5
Diabetes Australia(66)
6
Australien Government, Human Service Department(67). 
7
Personal communication 
with professor Chittaranjan Yajnik, Pune.
 8
Personal communication with the pediatrician endocrinologist doctor Ekkekard 
Zôllner.  
 
Incidence of Type 1 Diabetes 
In 2007, IDF estimated incidence of T1D among children less than 15 years of age in countries all over 
the world, Table 12. According to the estimates from IDF, Norway had the highest incidence of T1D 
with 27.9 per 100 000 among the countries in our study. Norway was accompanied by Canada with 
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21.7 per 100 000, Australia with 20.9 per 100 000 and the USA with 16.1 per 100 000 as high 
incidence countries. The country in South America, Argentina, had an intermediate incidence on 6.8 
per 100 000. The Asian country, India, had the lowest incidence of the countries who had data in our 
study with 4.2 per 100 000. This trend of incidence among the countries follows the trend found by 
the DIAMOND project group (9). The DIAMOND study points out that in their data they lack 
information about incidence in the countries with the largest child populations and the lowest GDP. 
When 1 out of 10 children die before the age of five it is difficult to get reliable data on the incidence 
of diabetes among children. This is the situation for the countries in Africa and South- and East Asia. 
When the children die of acute respiratory infections or diarrhea this can mask the symptoms of 
diabetes and whether the children had diabetes or not, remain unrecognized (9).  
Table eight; population and gross domestic product in 2012 in studied countries, shows that there 
are different ethnic groups in the studied countries. Genetics and environmental factors influence 
the incidence of DM, both T1D and T2D(9).  
 
Table 12: International Diabetes Federation incidence on type 1 diabetes (T1D) in children 0-14 
years, for 2007 (*) 
 
Country Incidence of T1D among children <15 years of age 
Norway 27.9 per 100 000
 
Argentina 6.8 per 100 000
 
Australia 20.9 per 100 000
 
Canada 21.7 per 100 000
 
India 4.2 per 100 000
 
Rwanda No data available 
South-Africa No data available 
USA 16.1 per 100 000
 
(*) 
IDF estimates for 2007 (68). 
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Prevalence of Type 1 Diabetes 
According to Table 12, Norway was estimated to have the highest incidence of T1D among children 
less than 15 years of age in 2007. The country also had the highest percentage of the childhood 
population between 0 – 14 years with T1D in 2007, Table 13. However, Norway, which is a small 
country in population compared to India, had the lowest number of children, less than 15 years of 
age, with T1D in our study. India which had the lowest incidence of T1D in our study had the highest 
population of children between 0 - 14 years, and therefore the highest number of children under 15 
years of age with T1D. The prevalence numbers are from the IDF Diabetes Atlas estimates for 2007. 
Due to lack of national registers, which register prevalence of T1D, we could only find official data 
from Norway, Canada and the USA. The data from Canada and the USA do not distinguish between 
T1D and T2D or give data on the age group less than 15 years of age as a whole.  
 
Table 13: Prevalence of diabetes mellitus in studied countries 
 
COUNTRY TOTAL PREVALENCE OF TYPE 1 DIABETES IN CHILDREN <15 YEARS 
 
IDF estimates for 2007 (000’S)
1 
IDF estimate   re a e  e 
 er  o   atio  0 -   
 ears      2007
2 
NATIONAL DIABETES REGISTER 
Norway  1,6 0.18 Ca 2500
3
  
Argentina  4,4 0.04 No data available 
Australia 5,2 0.13 No data available 
Canada 8,4 0.15 
2008/2009, T1D and T2D, 1-9 years: 0.2 %, 5201 children. 
10-19 years: 0.5 %, 20492 children. > 1 - < 20 years: 0.3 %, 
25693 children and adolescents
4
.  
India 92,3 0.003 No data available 
Rwanda 0,2 0.05 No data available 
South-
Africa 
5,0 0.03 No data available 
USA 62,6 0.10 
No data available form register  
*215 000 <20 years have DM, T1D or T2D. 2010. 0.26 % of 
all people in this age group in US
5. 
1
IDF estimates for 2007(68).
2
Estimated prevalence per 2007 divided to estimated child population 0 – 14 years. Numbers 
are rounded to two decimals.
3
Personal communication with Senior Consultant Torlid Skrivarhaug MD PhD.
 4
Public Health 
Agency Canada (69). 
5National Diabetes Factsheet, US(70). 
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Patient organizations 
In all the countries in our study there were patient organizations for people with T1D. All the patient 
organizations were members of IDF. There were differences among the organizations in the studied 
countries. However, all of them worked for better knowledge and treatment of T1D among people 
with T1D, their families and among health personnel.  Some of the organizations also arranged 
diabetes camps and different social happenings, and had local organizations to support their 
members where they live. Social networking and support for children and adolescents with T1D 
could be important for better compliance in treatment and also better social wellbeing.  Patient 
organization for people with chronically diseases is an important tool to complement the treatment 
and follow up from the national health care systems. Patient organization for patient with T1D may 
also be an important tool to integrate use of ISPADs guidelines for children and adolescents with 
T1D.  
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Table 14: Patient organizations for patients with diabetes mellitus in the countries studied.  
 
COUNTRY PATIENT ORGANIZATIONS 
 
National organizations for 
patients with T1D?
1 
Local organizations for 
patients with T1D? 
Support offered the children and their parents? 
Norway  
Yes, the Norwegian 
Diabetes Association
2
. 
Yes. Norwegian Diabetes 
Association is divided into 
19 county branches which 
are divided into several 
small local groups. 
Diabetes magazine and websites with information 
about diabetes and diabetes management (including a 
websites on young diabetes). Camps. Advocacy help, 
courses, educational programs, social happenings. 
Argentina  
Yes, Federación Argentina 
de Diabetes (The 
Argentine Diabetes 
Federation)
3
. 
No data available. 
Diabetes magazine and websites with information 
about diabetes and diabetes management. Camps. 
Australia Yes, Diabetes Australia
4
. 
Diabetes Australia is 
divided into departments 
in each state. Local 
community support group 
only available in certain 
states. 
Diabetes magazine and websites with information 
about diabetes and diabetes management. Camps. 
Preferred access and discounts for diabetes products 
and services, discounts on publications, travel, health 
insurance and footwear, amongst others. Sales and 
advice on blood glucose meters. 
Canada 
Yes, Canadian Diabetes 
Association
5
. 
Yes. The Canadian 
Diabetes Association is 
divided into regional 
departments. 
Diabetes magazine and websites with information 
about diabetes and diabetes management. Camps. 
Special offers and discount on diabetes products, 
contact centre available on phone for information 
about diabetes, local events. 
India 
Yes, Diabetic Association 
of India
6
. 
No data available. 
Diabetes journal which include educational section for 
non-medical members. Education for diabetics patient, 
courses for family physicians.  
Rwanda 
Yes, Rwanda Diabetes 
Association
7
. 
No data available. 
Publish free of charge leaflets providing basic 
information about diabetes to hospitals, dispensaries, 
and health care centers. Works for insulin accessibility 
for people with diabetes. The first diabetes camp was 
held January 2013. Education of health personell.  
South-Africa 
Yes, Diabetes South 
Africa
8
. 
Yes, Diabetes South Africa 
is divided into 8 branches. 
Publications and literature, websites with information 
about diabetes and diabetes management. Camps. 
Lectures and workshops, support groups.  
USA 
Yes, American Diabetes 
Association
9
. 
Yes, there are local offices. 
Diabetes magazines and websites with information 
about diabetes and diabetes management. Camps. 
Local events, website for kids and parents. 
1 
All the patient organizations are found through IDF web pages (71). 
2
The Norwegian Diabetes Associations web pages 
(72).
3
The Argentine Diabetes Federation web pages (73).
4
Diabetes Australia Web pages (74).
5
Canadian Diabetes Association 
(75). 
6
Diabetic Association of India web pages (76). 
7
Rwanda Diabetes Association web pages (77). 
8
Diabetes South Africa 
web pages (78). 
9
American Diabetes Association web pages (79).  
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National diabetes register 
In some of the countries and hospitals that have been compared in this study, it has been difficult to 
find the exact data about diabetes and the effect of the disease for the patients.  Four out of eight 
countries in this study have a national diabetes register. These countries are Norway, Australia, 
Canada and India. The register in Canada, however, does not register acute and late complications 
for children and adolescents less than 15 years of age. The data which the register in India registers 
was not available. 
In the report “Good health registries – good health” from The Norwegian government and the 
Norwegian Institute of Public health, 2010, it says that: “One of the most important sources to new 
knowledge about disease, treatment effect and quality services, are national health registries.” This 
report includes a plan for improving all health registries in Norway from 2010-2020 (80). 
 
Table 15: Registers for diabetes in studied countries 
 
COUNTRY REGISTER FOR DIABETES 
  
Is there a national diabetes register? If yes, what data is registered? 
Norway  
The Norwegian Childhood Diabetes Register, the Norwegian 
Diabetes Register for adults.
1
 
Incidence, annual data on diabetes 
care, quality indicators for diabetes 
care: HbA1c, acute complications, 
screening for late complications, 
screening for associated diseases. 
Argentina  No ---- 
Australia 
National Diabetes Register (obtain information from the 
National Diabetes Services Scheme and the Australasian Pediatric 
Endocrine Group (APEG) State-based registers.
2
 
Collects information about people who 
use insulin in the treatment of their 
diabetes. Incidence, acute and late 
complications 
Canada National Diabetes Surveillance System (NDSS)
3
. Incidence, prevalence, other. 
India 
Indian Council of Medical Research, Registry of People with 
Diabetes with Young Age at Onset
4
. 
Data not available. 
Rwanda No ---- 
South-
Africa 
No ---- 
USA No ---- 
1
National service environment for medical quality register (81, 82). 
2
Australian Institute of Health and Welfare (83).  
3
Public 
Health Agency of Canada (84).
4
Personal communication with professor Chittaranjan Yajnik, Pune. 
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Part 3: Results 
Diabetic ketoacidosis at diagnosis 
DKA is unfortunately a quite common presentation of T1D in children. Only studies and diabetes 
registries can state the incidence exactly. 
Table 16: Proportion of children having diabetic ketoacidosis (DKA) at diagnosis  
Country, Hospital 
Proportion (%) of children 
having DKA at diagnosis 
Norway, OUH, 2011 13 
Norway, SUH, 2011 6 
Norway, Buskerud Central Hospital, 2010 33 
Norway, Elverum, 2011 24 
Argentina, Hospital de Niῆos, 2011 30 
Argentina, Hospital Narciso Lopes, 2011 90 
Australia, Royal Childrens Hospital (Melbourne), 2009 28
 
 
Australia, Alice Springs Hospital, 2009 Data not known
 
Australia, John Hunter Hospital (Newcastle), 2010 Data not known
 
Canada, British Colombia Children's hospital, 2010 20
 
Canada, Hospital for Sick Children, 2010 18
 
South Africa, Tygerberg Hospital, 2010 Most
 
Rwanda, University Teaching Hospital of Butare, 2010 100
 
USA, Childrens Hospital of Orange County, 2009 20-25 
USA, University of Minnesota Amplatz Children's Hospital, 2009 < 15
 
India, King Edward Memorial Hospital, 2013 80 
 
All hospitals visited, except from UTHB (Rwanda), used the ISPAD criteria for DKA, as shown in Table 
5. At UTHB (Rwanda) they did not have a specific protocol for diabetes care and based their 
diagnostics on clinical symptoms such as impaired consciousness, dehydration, acidotic breathing, 
hyperglycemia, glucosuria and on occasion ketonuria in acutely ill patients. Bicarbonate and pH were 
not measured of unknown reasons.  
The proportion of children presenting with DKA varied considerably among the different hospitals 
visited. SUH (Norway) reported in 2011 the lowest proportion of 6%, while UTHB (Rwanda) reported 
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that all children diagnosed with T1D had DKA. Close by, TH (South-Africa) reported that most of their 
patients presented with DKA and at Hospital Narciso Lopes (Argentina), 90% of children had DKA at 
diagnosis. At KEM (India), 80% of the children had DKA at diagnosis. Between these extremes the 
proportions from the remaining 9 hospitals with known data varied from 15% (UofM (Minnesota, 
USA) reported < 15%) to 33%. The mean proportion when adjusting the answer from CHOC 
(California, USA) to 23%, the answer from U of M (Minnesota, USA) to 15% and the answer from TH 
(South Africa) to 100%, was 41%. 
  
Acute complications 
 
Table 17: Annual proportion of diabetic ketoacidosis (DKA) and severe hypoglycemia among children 
with type 1 diabetes 
Country, Hospital 
DKA, annually 
proportion (%) 
Severe hypoglycemia with 
unconsciousness with/without 
convulsions, annually proportion (%) 
Norway, OUH, 2011 6 6
 
Norway, SUH, 2010 4 9 
Norway, Buskerud Central Hospital, 2010 6
 
3 
Norway, Elverum, 2010 4
 
1
 
Argentina, Hospital de Niῆos, 2011 10
 
< 1
 
Argentina, Hospital Narciso Lopes, 2011 20
 
10
 
Australia, Royal Childrens Hospital (Melbourne), 2009 Data not available
 
Data not available
 
Australia, Alice Springs Hospital, 2009 Data not available
 
Data not available
 
Australia, John Hunter Hospital (Newcastle), 2010 Data not available
 
Data not available
 
Canada, British Colombia Children's hospital, 2010 Data not known
 
Data not known
 
Canada, Hospital for Sick Children, 2010 5-12
 
10-15 
South Africa, Tygerberg Hospital, aug-nov 2010 16 Hardly ever
 
Rwanda, University Teaching Hospital of Butare, 2010 Data not known
 
Data not known
 
USA, Childrens Hospital of Orange County, 2009 < 1
 
5
 
USA, University of Minnesota Amplatz Children's Hospital, 2009 4 8
 
India, KEM Hospital, 2013 < 5 
 
< 5 
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The annual proportion of children admitted with DKA varied from < 1% to 20% among the hospitals 
visited in our trial.  
The annual proportion of children admitted with severe hypoglycemia varied from none (hardly ever) 
at TH (South Africa) to 15% at SickKids (Toronto, Ontario, Canada). In Rwanda this number was 
unknown.  
In Argentina and South Africa, children with DKA presented more often than children with severe 
hypoglycemia. In Canada and the USA, it was the other way around. Children with severe 
hypoglycemia were admitted more often than children with DKA. 
 
Treatment and treatment goals 
Seven out of 15 hospitals reported that 100% of their patients were on MIT. Ten hospitals out of 15 
reported that more than 50% of their patients were on MIT.  
In Norway, none used syringes and the majority of patients used insulin pumps. Syringes were not in 
use at UofM (Minnesota, USA) either. At ASH (Northern Territory, Australia) and at UTHB (Rwanda), 
100% of patients used syringes in treatment. At both hospitals visited in Argentina, ASH (Northern 
Territory (Australia), TH (South Africa) and UTHB (Rwanda) insulin pumps were not available for 
children with T1D.  
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Table 18: Proportion of patients with type 1 diabetes on various treatment regimens 
 
Country, Hospital 
Syringes (%) Insulin pen (%) Insulin pump (%) 
Proportion of 
patients on multi-
injection therapy 
(%) 
Norway, OUH, 2011
 
0 30 70 100 
Norway, SUH, 2011
 
0 49 51 100 
Norway, Buskerud Central Hospital, 
2010
 0 23 77 100 
Norway, Elverum, 2011
 
0 79 21 100 
Argentina, Hospital de Niῆos, 2011
 
Data not available Data not available 0 100 
Argentina, Hospital Narciso Lopes, 2011
 
Data not available Data not available 0 90 
Australia, Royal Childrens Hospital 
(Melbourne), 2009
 Data not available Data not available 30 50 
Australia, Alice Springs Hospital, 2009
 
100 0 0 0 
Australia, John Hunter Hospital 
(Newcastle), 2010
 Data not available Data not available 38 94 
Canada, British Colombia Children's 
hospital, 2010
 Data not available Data not available 32 36 
Canada, Hospital for Sick Children, 2010
 
Data not available Data not available 30 (-40) 40 (-50) 
South Africa, Tygerberg Hospital, 2010
 
25 75 0 100 
Rwanda, University Teaching Hospital of 
Butare, 2010
 100 0 0 0 
USA, Childrens Hospital of Orange 
County, 2009
 52 18 30 45 
USA, University of Minnesota Amplatz 
Children's Hospital, 2009
 0 33 67 100 
India, KEM Hospital, 2013 
100 (in combination 
with insulin pen 
100 (in combination 
with syringes) 
0* > 95 
*10 children used insulin pump 
The treatment goal stated by ISPAD is HbA1c < 7.5%. Out of 16 hospitals visited, 11 followed 
ISPAD’s goal. The two hospitals visited in Canada used Canadian treatment goals. CHOC 
(California) in the USA used American treatment goals (Table 3). At UTHB (Rwanda) there 
was, as mentioned earlier, no specific protocol for diabetes care. At John Hunter Hospital 
(Newcastle, Australia) the treatment goal for children was < 7%.  
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Table 19: Proportion of patients reaching the treatment goal of HbA1c < 7.5% as stated by ISPAD* 
 
Country, Hospital 
Proportion (%) of patients achieving 
treatment goals 
Norway, OUH, 2011 23
 
Norway, SUH, 2011 33
 
Norway, Buskerud Central Hospital, 2010 23
 
Norway, Elverum, 2010 20 
USA, University of Minnesota Amplatz Children's Hospital, 2009 22
 
Argentina, Hospital Narciso Lopez, 2011 60
 
Argentina, Hospital de Niῆos, 2011 65 
South Africa, Tygerberg Hospital, 2010 9 
Australia, The Royal Children´s Hospital in Melbourne, 2009 ~ 30 
Australia, Alice Springs Hospital, 2009 < 50 
India, KEM Hospital, 2013 15-20 
*International Society for Pediatric and Adolescent Diabetes 
 
Table 20: Guidelines used and proportion of patients reaching the treatment goal in hospitals not 
using ISPAD’s* treatment goal 
Country, Hospital Guidelines or treatment 
target used 
Proportion (%) of patients achieving 
treatment goals 
USA, Children's Hospital of Orange County, 
2009 
ADA guidelines 30 
Canada, British Columbia Children's 
Hospital, 2010 
CDA Guidelines Data not available 
Canada, Hospital for Sick Children, 2010 CDA Guidelines Data not available
 
Australia, John Hunter Hospital, Newcastle, 
2010 
HbA1c <7 % Data not known
 
Rwanda, University teaching hospital of 
Butare, 2010 
No specific protocol for 
diabetes care 
Data not known
 
*International society for pediatric and adolescent diabetes 
 
The treatment target used by ADA and CDA are age specific, as presented in Table 3 and 
Table 4. Children over the age of 13 years strive to achieve HbA1c below 7.5%. Younger 
children have a higher treatment target. Different treatment targets between different 
hospitals make it harder to compare results. It must be taken into account when comparing 
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the amount of children reaching treatment goals at for instance CHOC (California, USA) and 
JHH (Newcastle, Australia). 
At UTHB (Rwanda) it was not possible to measure HbA1c, and therefore impossible to 
estimate a proportion of patients achieving ISPAD’s target. The BG measured indicated, 
however, an HbA1c above 7.5%.  
The results varied in general from 9% at TH (South Africa) to 65% at Hospital de Niῆos 
(Argentina). The number from TH (South Africa) was based on a few case reports and the 
number from Hospital de Niῆos (Argentina) was an estimate. Uncertainty about the true 
value must be assumed. The proportions reported from hospitals with registries varied from 
22% to 33%.   
 
Long-term complications 
As showed in table 6, ISPAD has detailed guidelines concerning the screening for DR and diabetic 
nephropathy. The guidelines from 2009 are unclear on recommended screening for neuropathy in 
children with T1D.  
Alice Springs Hospital (Northern Territory, Australia) and UTHB (Rwanda) were the only two hospitals 
without any screening programs for late complications.  
Out of the three complications screened for, neuropathy was most often omitted. Five hospitals did 
not screen for neuropathy, even though they screened for DR and nephropathy. RCH (Melbourne, 
Australia) and JHH (Newcastle, Australia) followed Australian guidelines when it came to screening 
for late complications. They evaluated peripheral nerve function annually in the presence of poor 
metabolic control. This is in accordance with Australian guidelines.  
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At Hospital for SickKids (Toronto, Ontario, Canada) they screened for retinopathy when indicated. 
Our study didn’t answer what the indications were. It must be assumed that they screened in case of 
poor compliance and metabolic control. Screening for nephropathy was done yearly from 12 years of 
age.  
At CHOC (California, USA) they screened for retinopathy and nephropathy annually five years after 
diagnosis independently of age at diagnosis.  
At KEM (India), fundoscopy was done annually to screen for DR. At what age or duration of T1D 
screening was started, is unknown. Nephropathy was screened for using albumin-creatinine-ratio in 
urine combined with serum creatinine. In screening for neuropathy, foot examination, including 
testing for sensation of pain and vibration, was used. How often screening for nephropathy and 
neuropathy was done, is unknown.  
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Table 21: Screening programs for long-term complications among children with type 1 diabetes 
Country, Hospital Retinopathy Nephropathy Neuropathy 
Norway, OUH, 2011
 
X X No 
Norway, SUH, 2011
 
X X No 
Norway, Buskerud Central Hospital, 2010
 
X X X 
Norway, Elverum, 2011
 
X X No 
Argentina, Hospital de Niῆos, 2011
 
X X X 
Argentina, Hospital Narciso Lopes, 2011
 
X X X 
Australia, Royal Childrens Hospital (Melbourne), 2009
 
X X In risk patients 
Australia, Alice Springs Hospital, 2009
 
No No No 
Australia, John Hunter Hospital (Newcastle), 2010
 
X X In risk patients 
Canada, British Colombia Children's hospital, 2010
 
X X Data not available 
Canada, Hospital for Sick Children, 2010
 
When indicated X Data not available 
South Africa, Tygerberg Hospital, 2010
 
X X X 
Rwanda, University Teaching Hospital of Butare, 2010
 
No No No 
USA, Childrens Hospital of Orange County, 2009
 
X X No 
USA, University of Minnesota Amplatz Children's Hospital, 2009
 
X X No 
India, KEM Hospital, 2013 X X X 
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Table 22: Proportion of children with type 1 diabetes having long term complications 
Country, Hospital Retinopathy Nephropathy Neuropathy 
Norway, OUH, 2011
 
0 0 0 
Norway, SUH, 2011
 0 0 0 
Norway, Buskerud Central Hospital, 2010
 0 0 0 
Norway, Elverum, 2011
 0 0 0 
Argentina, Hospital de Niῆos, 2011
 
< 1% 15 % 12 % 
Argentina, Hospital Narciso Lopes, 2011
 
0 3-4 % 2 % 
Australia, Royal Childrens Hospital (Melbourne), 2009
 Data not available Data not available Data not available 
Australia, Alice Springs Hospital, 2009
 Data not known Data not known Data not known 
Australia, John Hunter Hospital (Newcastle), 2010
 Data not available Data not available Data not available 
Canada, British Colombia Children's hospital, 2010
 Data not available Data not available Data not available 
Canada, Hospital for Sick Children, 2010
 Data not available Data not available Data not available 
South Africa, Tygerberg Hospital, 2010
 Data not known Data not known Data not known 
Rwanda, University Teaching Hospital of Butare, 2010
 Data not known Data not known Data not known 
USA, Childrens Hospital of Orange County, 2009
 
0 0  0 
USA, University of Minnesota Amplatz Children's Hospital, 2009
 0 0 0 
India, KEM Hospital, 2013 Data not available* Data not available* Data not available* 
*Ten years after diagnosis, 20-25% of children with type 1 diabetes was reported to have late complications. Distribution is 
unknown.  
 
Our data show that even if most hospitals visited did screening for late complications, few registered 
and kept record of the data. It might be registered in the patient’s journal and used in follow up of 
the individual patient, but not possible to observe in an overall view for patients from that area.  
KEM (India) and the two hospitals in Argentina were the only hospitals reporting late complications 
in children with T1D. At Hospital de Niῆos (Argentina), all three late complications were observed. 
CHOC (California, USA) followed up some patients with microalbuminuria, but no one with diabetes 
nephropathy (see Table 7 for definitions).  
Hyperglycemia, hyperlipidemia and hypertension are examples of risk factors for late complications. 
Hypertension is seen in children with T1D. It is therefore important to screen for and treat if present. 
ASH (Northern Territory, Australia) and UTHB (Rwanda) did not screen for hypertension. Our study 
didn’t find out whether KEM (India) and the hospitals in the USA and Canada did screening for 
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hypertension or not.  At ASH (Northern Territory, Australia), TH (South Africa) and UTHB (Rwanda) 
the amount of children with hypertension was unknown. Hypertension in children is defined as blood 
pressure above the 95% percentile. 
 
Table 23: Proportion of children with type 1 diabetes having hypertension 
Country, Hospital 
Proportion of children 
having hypertension 
Norway, OUH, 2011
 
2 % 
Norway, SUH, 2011
 7 % 
Norway, Buskerud Central Hospital, 2010
 4 % 
Norway, Elverum, 2011
 1 % 
Argentina, Hospital de Niῆos, 2011
 
5 % 
Argentina, Hospital Narciso Lopes, 2011
 
1-3 % 
Australia, Royal Childrens Hospital (Melbourne), 2009
 Data not available 
Australia, Alice Springs Hospital, 2009
 Data not known 
Australia, John Hunter Hospital (Newcastle), 2010
 Data not available 
Canada, British Colombia Children's hospital, 2010
 Data not available 
Canada, Hospital for Sick Children, 2010
 Data not available 
South Africa, Tygerberg Hospital, 2010
 Data not known 
Rwanda, University Teaching Hospital of Butare, 2010
 Data not known 
USA, Childrens Hospital of Orange County, 2009
 
5-10% 
USA, University of Minnesota Amplatz Children's Hospital, 2009
 1 % 
India, KEM Hospital, 2013 < 5% 
 
The reported proportion of children with hypertension at the four hospitals in Norway gives a mean 
value of 4%. The Norwegian hospitals reported both among the highest and the lowest proportions 
in our study. The lowest proportion reported was 1%. U of M (Minnesota, USA) reported that 
between five and 10% of children with T1D had hypertension. This, along with the SUH’s (Stavanger, 
Norway) proportion of seven percent, is the highest proportions reported.  
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Diabetes team 
 
Table 24: Multidisiplinary diabetes teams in the different hospitals  
Country, Hospital 
Diabetes 
team 
Doctor 
Diabetes 
nurse 
Nutritionist 
Social 
worker 
Psychologist 
Diabetes 
educator 
ISPAD recommendations Y Y Y Y Y Y   
Norway, OUH, 2011
 
Y Pediatrician Y Y Y Y   
Norway, SUH, 2011
 
Y Pediatrician Y Y Y Y   
Norway, BCH, 2010
 
Y Pediatrician Y Y Y Y  
Norway, Elverum, 2011
 
Y Pediatrician Y Y Y None   
Argentina, Hospital de 
Niῆos, 2011
 
Data not 
available 
Y, specialiced 
in diabetes 
 Data not 
available 
 Data not 
available 
 Data not 
available 
 Data not 
available 
  
Argentina, Hospital N. 
Lopes, 2011
 
Data not 
available 
Y, specialiced 
in diabetes 
Data not 
available 
Data not 
available 
Data not 
available 
Data not 
available 
  
Australia, RCH, 2009
 
Y Pediatrician Y Y Y On request   
Australia, ASH, 2009
 
No Pediatrician None Y None On request Y 
Australia, JHH, 2010
 
Y Pediatrician None Y Y On request Y 
Canada,BCCH, 2010
 
Y 
Y (unknown 
speciality) 
Regular 
nurse 
Y Y On request   
Canada, SickKids, 2010
 
Y Pediatrician Y Y Y Y   
South Africa, TH, 2010
 
Y Pediatrician Y Y Y None   
Rwanda, UTHB, 2010
 
No Pediatrician 
Regular 
nurse 
None None None   
USA, CHOC, 2009
 
Y 
Y (unknown 
speciality) 
Y Y Y Y   
USA, U of M, 2009
 
Y 
Y (unknown 
speciality) 
Y Y Y Y   
India, KEM Hospital, 2010
 
Y Pediatritian 
Regular 
nurse 
Y None None Y  
UUH: Ullevål University Hospital, SUH: Stavanger University Hospital, BCH. Buskerud Central Hospital, RCH: Royal Children’s 
Hospital, ASH: Alice Springs Hospital, JHH: John Hunter Hospital, BCCH: British Columbia Children’s Hospital, SickKids: 
Hospital for Sick Children, TH: Tygerberg Hospital, UTHB: University Teaching Hospital of Butare, CHOC: Children’s Hospital 
of Orange County, U of M: University of Minnesota Amplatz Children’s Hospital, KEM Hospital: King Edward Memorial 
Hospital. Y = yes, profession part of the multidisciplinary team 
 
Because ASH (Northern Territory, Australia) followed up very few children with DM they did not have 
a fixed multidisciplinary team. Nevertheless, whenever a child visited the outpatient clinic or was 
admitted, a pediatrician, a diabetes educator and a dietician at the hospital functioned together as a 
team. If the family was aboriginal, an aboriginal liaison officer also participated in the team.  
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At UTHB (Rwanda) there were no endocrinologists, specialized diabetic nurses, psychologists, 
nutritionists or social workers at the hospital.  
The nurses working at BCCH (Vancouver, British Colombia, Canada), UTHB (Rwanda) and KEM (India) 
were not specialized in diabetes like ISPAD recommends. At KEM (India) they also lacked a 
psychologist and a social worker.  
Out of the professions ISPAD recommends to constitute the treatment team, psychologists were 
most often missing. Seven hospitals had a psychologist at least in a part time job. At all but four 
hospitals, psychologists were available on request.  
All but the two hospitals in Argentina had access to interpreters if needed, among the hospitals we 
have that information about. We miss information about interpreters from UTHB (Rwanda), KEM 
(India) and the two hospitals in Canada. At Alice Springs Hospital (Northern Territory, Australia) they 
had access to an interpreter at the hospital if the patient was indigenous. Otherwise, interpreters 
were available in town.   
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Part 4: Discussion 
Use of guidelines in general 
Among the 16 hospitals visited, 15 hospitals used guidelines in their care for children with T1D. At 
UTHB (Rwanda) there was no specific protocol for diabetes care. Hospitals in the USA followed 
American guidelines. Hospitals in Canada followed Canadian guidelines. Hospitals in Australia 
followed Australian guidelines. The remaining hospitals reported that they followed the guidelines 
stated by ISPAD. ADA and CDA have age-dependent treatment goals. Besides that, there are no 
major differences between these different guidelines related to the subjects of this thesis.  
At UTHB (Rwanda) the doctor was in charge of everything concerning the treatment when a child 
with T1D was admitted. For acute management of DKA, the guidelines used at UTHB were described 
in the book “Pediatric Emergencies” by Francois DeVilliers. Because of the low incidence of T1D in 
Rwanda, the physicians at UTHB saw few children with T1D. Only four cases of new onset T1D were 
registered at UTHB (Rwanda) between November 2008 and October 2010. Naturally, a doctor will 
improve his/her clinical experience if seeing a large quantity of children with diabetes. One could 
think that guidelines would be especially important when clinical experience is limited. Because of 
lack of medical equipment and financial challenges this might, however, be hard to practice. At UTHB 
(Rwanda) it was not possible to measure HbA1c due to lack of equipment. Home BG monitoring was 
not used and simple urine glucose testing was not performed regularly. Physicians and nurses in 
Rwanda deserve credibility for the effort and work despite lack of frequent experience and 
technological equipment. 
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Variations in diabetic ketoacidosis at diagnosis  
The proportion of children with DKA at diagnosis does not tell anything about the diabetes care in 
the hospitals. However, it can tell something about the pre-hospital health care and might also tell 
something about the knowledge about DM in an area. Incidence may correlate to knowledge. In 
Rwanda and South Africa, where 100% of newly diagnosed children with T1D had DKA, there was 
unfortunately no data available on the incidence of childhood DM. India was reported to have 80 % 
of the children less than 15 years of age presenting with DKA at diagnosis. The proportion of children 
presenting with DKA is generally lower in western, high incidence countries (Table 12 and Table 16). 
Incidence of T1D among children has in some studies been found to correlate with the proportion of 
children having DKA at diagnosis in a country (85, 86). The studies show that in countries with high 
incidence of T1D there were lower percentages of children having DKA at diagnosis and vice versa. 
The same trend was seen in this study. The high incidence countries for T1D among children under 
15 years of age in our study was Norway on the top followed by Canada, Australia and the USA, while 
Argentina and India are reported as intermediate- and low incidence countries. There are no data 
available from Rwanda and South Africa in our study, but data from the DIAMOND project group 
shows that Africa is a low incidence area for T1D among children (9). In an area with low incidence of 
T1D there may be less knowledge about the disease, and therefore less awareness of the symptoms 
both among the general population and among health professionals. Less knowledge may lead to 
people seeking medical help later in the process or medical delay at the general physician or at local 
health centers.  Medical delay may be due to misinterpretation of the symptoms for DKA. DKA in 
undiagnosed children might for example be misinterpreted as gastroenteritis or cerebral malaria.  
Physician density may also be an explanation for the variations in frequency of DKA at diagnosis. If 
the doctor is far away, patients may wait longer until they seek help and their situation might be 
more critical when seeing the doctor. The patients followed up at UTHB (Rwanda) could live in a five 
hour walking distance from the hospital. One can expect that patients with this acute complication 
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never reach hospital.  In our study, the country with the lowest physician density, Rwanda, also had 
the highest frequency (100%) of DKA at diagnosis among children. The same trend could be seen in 
South Africa and India. In Argentina, however, where Hospital N. Lopez reported 90% DKA at 
diagnosis among children, they had the second highest physician density among the countries in our 
study. Along with physician density per population, the geographical distribution of physicians in 
rural and urban areas must be considered. The high frequency of DKA at Hospital N. Lopez despite 
Argentina’s high physician density could be due to an unequal distribution of physicians among the 
population.   
Other factors such as social, economical and geographical differences may also explain why there is 
this big variation in DKA at diagnosis between the hospitals and the countries in our study. 
 
Treatment regimens and financial support 
ISPAD recommend MIT as insulin replacement therapy. The aim with the therapy is to be as close to 
physiological insulin production as possible. This is best managed through insulin pump (33). Use of 
insulin pump has been showed to have greater treatment satisfaction compared to MDI. However, 
the outcome on metabolic control is the same when using insulin pump as when using MDI (87).  
Despite the guidelines, there were differences among the hospitals in how insulin was administered. 
MIT administered through insulin pump is more expensive than use of insulin pen or syringes. MDI is 
also more expensive than a two-injection daily regimen which requires less insulin and insulin 
administration tools. 
Five hospitals did not offer insulin pumps to their patients. These hospitals were; Hospital de Niῆos 
and Hospital N. Lopez in Argentina, ASH (Northern Territory, Australia), TH (South Africa) and UTHB 
(Rwanda). The main reason for treatment without insulin pump was lack of financial support from 
the government or others to cover the cost for this expensive regimen. In Argentina, insulin pumps 
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were only available for those who had private health insurance or could pay for the pump 
themselves. In Australia, it was almost impossible to afford this regimen for patients without a 
private health insurance. The children and adolescents with diabetes in Australia needed to have the 
private health insurance one year prior to applying for the pump. Therefore, despite having health 
insurance, the patients had to wait before they could start with an insulin pump. In South Africa, 
insulin pumps were not financed through the public health care system. In Rwanda there was no 
national support system and the patients had to pay for all the diabetes treatment themselves. In 
India, they had 10 patients who used insulin pump. Why only these patients were using insulin pump 
is unknown, but may be due to financially reasons.  India had no governmental financed support 
system for patient with diabetes.  
Among the countries in our study, it seemed like the countries with the best national support system 
for diabetes treatment had most patients on the more expensive treatment regimens, like MIT 
administered through insulin pump and insulin pen. In Norway all the diabetes treatment was 
financed through the national health system. The patients only had to pay a standard deductible 
each year. When reaching this deductible, all the treatment was free of charge. At the hospitals in 
Norway all the patients followed the MIT regimen and were either on insulin pump or used insulin 
pen.     
In Canada however, the government financed the pump and some of the pump supplies when the 
child had had T1D for a year and when certain criteria were met. The government also supplied 
syringes, insulin pens and insulin. Despite the good national support system most children at the 
visited hospitals in Canada used the two-injection daily regimen due to other reason than economy.  
In the USA, private health insurances financed the diabetes treatment, including insulin pumps. The 
patients at CHOC (California, USA) and U of M (Minnesota, USA) had insurances to cover the 
expenditure related to pump therapy. Nevertheless, our study found a great difference between the 
numbers of patients using insulin pumps at these two hospitals. There was also a great difference 
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between the number of patients on MDI and two-injection daily regimen. These differences were 
related to other reasons than economy. 
 
Multi injection therapy 
Nine hospitals (56%) reported that they treat some of the children with insulin only two times per 
day.  
At RCH (Melbourne, Australia), most toddlers and young children were treated with twice daily 
insulin injections. The reason for this choice of treatment was partly to avoid focus on diabetes in the 
youngest. Most schools did not have school nurses to help with insulin administration. This made it 
hard to take injections during school hours. Furthermore, the youngest children had a quite regular 
schedule concerning meals and activity. It was therefore believed that insulin twice daily combined 
with an appropriate diet was optimal care for the youngest.  
At CHOC (California, USA), all children started with a two-shot regime. Eventually, the strategy for 
therapy was age dependent. Between the age of five and 14 years, patients injected insulin only 
twice daily. The reason was partly to do as few injections as possible and partly because of strict rules 
concerning who could give insulin. Only school nurses, parents and the child itself were allowed to 
set insulin at school and there weren’t enough nurses to administer insulin during school hours. With 
a two-shot regime, the child didn’t have to take insulin at school.  
In Canada, as in California, school personnel were not allowed to press the button on the insulin 
pump or give injections of insulin. This was the main reason reported from both BCCH (Vancouver, 
British Colombia) and SickKids (Toronto, Ontario) for children not on MIT.  
In Rwanda, all patients were given two injections of insulin per day. When recommending three 
injections per day, poorer compliance and outcome had been observed. Home BG monitoring was 
not used and dose adjustments were rarely performed due to difficulties in educating patients.  
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At ASH (Northern Territory, Australia), JHH (Newcastle, Australia), KEM (India) and Hospital Narciso 
Lopez (Argentina), no reason for choice of treatment regime was given.  
 
Treatment target, long term complications and national register 
ADA and CDA have higher limits for treatment target measured with HbA1c than ISPAD (Table 3 and 
4). This could be a reason for higher percentage of patients reaching treatment target in the 
countries using ADA and CDA guidelines. 
 The prevalence of late complications should correspond to the average HbA1c (5). In our study, the 
hospitals in Argentina had the highest percentage of patients reaching treatment target. These 
hospitals were also the only hospitals, along with KEM (India), who reported long term complications 
among children with T1D. KEM (India) reported long term complications in children with more than 
10 years from diagnosis. The numbers from Argentina were based on estimates from health 
personnel, and not from local databases or a national register. At the hospitals in Norway, the data 
were collected from the NCDR. Here, they did not report any long term complications among 
children with T1D. However, they reported approximately half of the percentage of children with T1D 
reaching treatment target, compared with Argentina. RCH (Melbourne, Australia) and CHOC 
(California, USA) reported numbers that showed the same correspondence between late 
complications and average HbA1c as in Norway. At the other hospitals, either the data on long term 
complication or the data on proportion reaching treatment goals among children with T1D was 
missing or unknown due to different reasons. 
Norway had the only hospitals in this study where the data was collected from a national register. 
Among the other hospitals, TH (South Africa) and U of M (Minnesota, USA) kept local databases on 
the patients’ HbA1c. At TH (South Africa) they started to register in August 2010 and they could not 
give any number regarding patients with long term complications. At U of M (Minnesota, USA) the 
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database registered patients with HbA1c < 7.5% and > 10%.  This register did not register long term 
complications. All the other values, regarding treatment target and long term complications, at the 
other hospitals in our study are based on estimates from health personnel. 
Conclusions cannot be made based on these observations in our study alone. Still, we can discuss 
some theories around our results. While using estimates based on clinical practice it might be easier 
to under- or overestimate the results. Before pediatricians in Norway started with systematic 
registering of diabetes care in Norway, at hospitals and on national basis, they often overestimated 
the results of children reaching treatment target (88). This might influence on further treatment and 
follow-up, and can give a higher risk for developing long term complications. As several studies have 
shown, strict monitoring of treatment in diabetes can prevent long term complications (5). The 
discrepancy between the amount of children reaching treatment goals and the amount of children 
with late complications in Argentina, constitute a logical gap. This indicates that the estimate on 
children reaching treatment target is too high, as seen in Norway before registration was started. 
This might show that a diabetes register at the hospitals and/or a national diabetes register, via 
awareness and increased focus, can help to prevent long term complications in children with 
diabetes.  
 
Limitations 
Our study had some limitations.  
The questionnaires used when interviewing health personnel working with diabetes care all over the 
world were not validated. Validation would increase the quality and reduce the chance of 
misunderstanding. In the work with making the questionnaire, it was tried out several times on 
diabetes nurses at OUH, and improved and corrected where needed before travelling abroad. We 
hope and believe that this work reduced the need for validation.  
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Another limitation is that different interviewers went to the different hospitals visited. Different 
focus and different personal qualities may influence the information collected. On the other side a 
standardized questionnaire was a strength in this study and reduced the challenge of using several 
different interviewers.   
A challenge, but not a limitation, is that information was collected in different years. We believe that 
this is of minor importance. A more limiting factor is the fact that some data have been hard to find. 
Some of this data isn’t known due to lack of registers, and some are not easily available, at least not 
to us. This complicates comparison between different hospitals and makes it harder to draw 
conclusions.  
 
Treatment strategy and compliance 
We have good indications to say that the approaches to treatment were very different in different 
countries visited. In Norway, the therapist communicated with the patient through motivational 
interviewing. The patients were in charge of their own treatment and the goal was to make the 
patient an expert on his/her own disease. The therapist coached and guided the patient when 
needed. If the metabolic control wasn’t satisfying, the patient was reminded of the possible long-
term complications and reeducated. The seriousness of T1D was in some cases neglected by the 
children and their parents so that they could be able to live their life as normal as possible. In 
Argentina, the therapists confronted the children more directly with the fact that they had a serious 
disease with possible complications, both now and later in life. In Rwanda, no information was given 
to the children and their families about the effect and complications of the disease. Because of the 
lack of equipment, children in Rwanda were in a lesser extent able to take control of the disease 
themselves. Home blood glucose monitoring was not used. In contrast, home blood glucose 
monitoring was the cornerstone and most essential part of treatment of T1D in Norway. Patients got 
equipment to measure their BG as many times as they wanted for free. The children in Argentina 
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were provided, by the pharmaceutical industry, with equipment to measure their BG three times a 
day. If more strips were needed, they had to pay themselves.  
 Our study cannot answer which treatment strategy is the most effective in reaching treatment goals. 
The important point, and the huge difference between treating DM and other diseases, is the fact 
that the therapist can do no more than guiding the patient in treatment. It is the patients’ day to day 
responsiveness, adjustments and actions that decide the long term outcome of the disease. The 
number of free BG strips doesn’t alone decide the prognosis. Compliance in treatment is everything.  
 
Diabetes mellitus – a model for management of chronic diseases 
There are extensive and thorough international guidelines concerning care for patients with DM. Still, 
it is hard to achieve that this care reaches all patients. It is even harder to achieve treatment goals 
because of the importance of compliance.  No other chronic disease has such detailed international 
guidelines. When the criteria for good treatment and registration are objective, benchmarking 
between units is an important tool to learn between different treatments clinics and to adjust and 
improve practice.  In this sense, diabetes care is a model for other chronic diseases.  
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Conclusion 
Among chronic diseases in children, diabetes is in a special position by having good international 
guidelines. Guidelines highlights important parameters in diabetes care and give a basis for 
establishing diabetes registers which can be compared internationally. Diabetes registers give 
objective data which can be used in highlighting challenges and in benchmarking. Benchmarking can 
influence diabetes care units to strive towards better results through increased awareness. Increased 
awareness can motivate diabetes care units to exchange experiences concerning diabetes care 
where guidelines, because of geographical and economical reasons, are hard to follow. We can 
achieve great results by learning from each other, both domestically and internationally.    
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Appendix 
Questionnairie – Diabetes in children 
 
 
 
QUESTIONNAIRE – DIABETES (T1D and T2D) IN CHILDREN: A GLOBAL PERSPECTIVE 17.11.10 
 
The questionnaire is designed to gather information about children with diabetes ≤ 15 years of age. 
The interview is in two parts. Each part should not last more than 1 hour. 
 
The first part is designed to map diabetes in children at a national or regional level. Each country has 
a number code (see list). The regions/counties/states are indicated by names.  The interviewer fills 
out this first part of the interview based on information available on the internet and other available 
sources. The information will then be quality assessed with the local informant. 
 
The second part is designed to map how children with diabetes are followed up at the local 
hospital/treatment centre. The interview contains multiple open, qualitative questions. The 
interview will therefore be tape-recorded. The tape recordings will be transcribed before the analysis 
takes place. 
 
The questionnaire does not ask for personal sensitive information. 
QUESTIONNAIRIE – DIABETES IN CHILDREN 
PART 1 
 Incidence 
 Prevalence 
 Mortality 
 National health 
 Patient organizations 
 Register for diabetes 
 Complications 
PART 2 
 Hospitalizations and number of beds 
 Diagnostics 
 Treatment and follow up 
 Treatment goals 
 Quality of life and mental health 
 Complications 
Universitetet i Oslo 
Det medisinske fakultet 
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Country (code): 
Region/county/state: 
Date: 
Informant: name/occupation  
Interview by: 
 
PART 1 
Incidence  
 
1. The annual incidence of the different types of diabetes in this country (enter the number and 
percentage) 
 Type 1 diabetes (T1D) 
 Type 2 diabetes (T2D) 
 Gestational diabetes 
 
2. The incidence of T1D and T2D among children under 15 years of age 
o The total incidence: 
o How is the distribution in the following groups of ages (estimated): 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o > 15 years 
 
3. What is the gender distribution among children with T1D and T2D in the country? 
 
 
4. What are the overall proportions of the following ethnicities in this country: 
o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
o Mixed (or unclassified) 
 
5. How many children with diabetes in this country are 
o White / European background (non-Hispanic whites)  
o Black / African background  
o Middle-East / North-African  
o Indian subcontinent  
o East-Asia 
o Middle- and South American (Hispanics)  
o Indigenous (specify) 
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o Mixed (or unclassified) 
 
Prevalence  
 
6. What is the prevalence of T1D and T2D among children in the following groups of age? 
o <5 years 
o 5-<10 years 
o 10-<15 years 
o ≥ 15 (adults) 
 
Mortality 
 
7. What is the average life expectancy in the country? 
o Women: 
o Men: 
 
 
8. What is the average life expectancy among patients diagnosed with T1D before   the age of 15?  
o Women: 
o Men: 
 
 
National health  
 
9. How many doctors per citizen? (This will differ depending on location; city, rural, town etc) 
 
10. Is there a geographical difference in availability of doctors? 
 
11.  What is the gross domestic product (GDP) of the county? 
 
12. What is the total expenditure on health as a percentage of the GDP? 
o Which proportion is financed by the public? 
o Which proportion is financed by private actors? 
 
13. Which proportion of the national budget is spent on health? 
 
14. Does the public health care system finance the costs associated with diabetes medication and 
equipment? 
o Yes 
o No 
 
15. If the answer is yes on question 14, which medication is financed?  
o Insulin 
o Yes 
 _________% financed 
o No 
o Antidiabetic drugs 
o Yes 
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 _________% financed 
o No 
 
          Glucagon 
o Yes 
               ____________% financed 
o No 
 
 
16. If yes on question 14, which of the following materials is financed  
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the insulin pump: (needle, catheter, reservoir etc): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
17. If the answer is yes on question 14, does the patient have to pay anything? If so, how much? (%) 
o Syringes: 
o Needles: 
o Insulin pen: 
o Insulin pump: 
o Materials for the insulin pump: (needle, catheter, reservoir...): 
o Home Blood Glucose meters: 
o Blood glucose test strips:  
o Finger-pricking devices: 
o Lancets for finger-pricking: 
o Continuous subcutaneous glucose monitoring devices: 
o Urine sticks to check for ketonuria: 
o Other:_____ 
 
18. Who brings the child to their check-ups? 
o Mum 
o Dad 
o Other:_______ (specify) 
 
19. Are there any laws/public rights for parents to get extra time off work to take their children to 
check ups?  
o Yes 
o No 
 
20. Are parents with chronic ill children allowed to take additional days off compared to the general 
population?  
o Yes (________number of additional days) 
o No 
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21. Are there national guidelines for the management of children with T1D and T2D? 
o Yes 
o No 
 
 
Patient organizations 
 
22. Are there any national organizations for patients with diabetes? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
23. Are there any local organizations for patients with T1D? 
o Yes 
o For children? 
o For children and adults? 
o For adults only? 
o No 
 
Comment:  
 
 
24. What do the patient organizations offer the children and their parents? 
o Websites  
o Telephone 
o Courses 
o Information meetings 
o Holiday offers / camps 
o Other:_________ 
 
Register for diabetes 
 
25. Is there a national diabetes register? 
o Yes, for children 
o Yes, for adults 
o Yes, for adults and children 
o No  
 
26. If yes, what data is registered? Does it include both T1D and T2D? 
 
 
 
Complications 
 
27. What is the incidence of acute diabetes complications among children under 15 years of age? 
o Diabetic ketoacidosis (with hospitalization)  
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o Severe hypoglycemia (unconscious with or without convulsions)  
 
28. What is the incidence of late diabetes complications among children under 15 years of age? 
(estimated percentage) 
o Retinopathy 
o Nephropathy 
o Neuropathy 
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PART 2 
 
Hospitalizations and number of hospital beds 
 
29. How many children <15 years with diabetes are admitted to hospital annually in the following 
wards (The total number of hospitalizations including rehospitalization) 
o Paediatric ward  
o Adolescents ward 
o Internal medical ward 
 
 
30. To what age are the children managed in the paediatric wards?_____ 
 
31. If there is an adolescent department, when do the children start attending and how long can 
they attend there? 
 
32. What is the maximum number of beds in the ward? _________ 
 
33. How often has the ward been full during the last 6 months? (regardless of the reason for the 
hospitalisation) 
 
34. How many children with diabetes are followed up at the local hospital today? 
 
35. How is the gender distribution among the children that are followed up at the local hospital? 
 
36. Who takes over the responsibility for the treatment and follow-up after the diagnosis of 
diabetes? 
o Specialist __________ (which type) 
o General practitioner (GP) 
o Other :________ 
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Diagnostics 
37. Who usually make the diagnosis? 
o General practice 
o Specialised health service 
o Nurse 
o Other:_________ 
 
38.  What is the average age at diagnosis? 
 
39. What are the classical symptoms that make the patient and his or her parents contact a doctor? 
 
40.  Which diagnostic criteria have to be fulfilled to set the diagnose of diabetes? 
 
           T1D 
o International guidelines; ISPAD (Blood glucose) 
o Other guidelines:__________________ 
 
T2D 
o International guidelines; ISPAD (Blood glucose) 
o Other guidelines:__________________ 
 
41. Where are recently diagnosed juvenile diabetics treated the first time? 
 
T1D 
o  Out-patients clinic 
o Hospital ward with beds 
 
T2D 
o Out-patients clinic 
o Hospital ward with beds 
 
42. If the patient is admitted to hospital, what is the average length of stay? 
T1D: 
T2D: 
 
43. Which diagnostic criteria do you use for DKA? 
o Hyperglycemia 
o Standard Bicarbonate (< 15 mmol) 
o pH (< 7,3) 
o Ketonuria / ketonemia 
44. What proportion of children has DKA at diagnosis? 
T1D: 
     T2D: 
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Treatment and follow up 
 
45. Who participates in the treatment and follow up of children with diabetes? 
o Nurse 
o Doctor 
o School nurse 
o Social worker 
o Nutritionist  
o Psychologist 
o Other:___________ 
o Multidisciplinary team 
 
46. Does the child with diabetes have one particular contact person? If yes, specify: 
o Yes:___________ 
o No 
 
47. When the diagnosis is made who is responsible for the follow-up? 
o Specialist (doctor / diabetologist) 
o Hospital doctor 
o Nurse 
o General practitioner  
o Other:_________ 
 
48.  Who are educated (at the time of the diagnosis, and after discharge)? 
o The child 
o Parents 
o School  
o School nurse 
o Nursery 
o Activity leaders/coaches 
o Others:___________ 
o No one 
 
49. Does the hospital have access to interpreters when they have patients that do not 
speak/understand English? 
 
50. How is the education organized? 
o Training in groups 
o Individual training 
o A combination of both 
 
51. When is a new education organized? (re-education) 
 
52.  Is carbohydrate counting used systematically when calculating the insulin bolus in relation to 
food? 
53. How is the education organized? 
o Training in groups 
o Individual training 
o A combination of a and 
Comment: 
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54. How much do parents participate in the treatment and follow up? 
 
55. Do the adolescents get contraceptive counselling? 
o Yes (comment ;)_____________ 
o No 
 
56. Have you experienced unintended pregnancies in this group of patients? 
o Yes (how many? what are the characteristics of these patients; ethnicity, socioeconomic 
status etc?) 
o No 
 
57. What types of treatment/treatment regimens are available for children with diabetes at the local 
hospital? 
o Syringes 
o Needles 
o Insulin pen 
o Insulin pump 
o Continuous Subcutaneous Glucose Monitoring  
o Others:_______________ 
o None 
 
58. How many patients use multi injection (insulin > 3 times a day) therapy? 
 
59. What proportion of the patients (in number and percentage) follow the different treatment 
regimens listed 
o Insulin pump: 
o Others: 
o None: 
 
60. Among the children under multi injection therapy what type of insulin preparations are used? (%) 
o Premixed insulin preparations  
o Intermediate-acting insulin + rapid-acting insulin 
o Analogues 
o Which combinations: ____________ 
o Are there any different strategies for insulin therapy concerning the child´s age? 
 
 
 
 
61. Who does the patient and his or her parents contact if the child is acute ill? 
o Specialist  
o Contact person 
o GP 
o Emergency room 
o Other:__________ 
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Treatment goals 
 
62. Are the ISPAD treatment goals adhered to?   
(ISPAD = International Society for Paediatric and Adolescent Diabetes) 
o Yes 
o No  
o If no, which guidelines are used______________ 
 
63.  What are the treatment goals 
o HbA1c < 7,5 % 
o Other:________ 
 
 
64. What proportions (%) of patients achieve the treatment goals? 
 
65. How often do the children attend diabetes health check ups? 
 
T1D:  ____________                    T2D:__________________ 
 
66. What proportions (%) of the patients attend their appointment? 
 
 
o Most patients 
o 50 % 
o Only a few 
 
 
67. Who does not attend? Why? What are the characteristics of these patients? 
 
 
 
 
 
 
68. Is there a screening program for autoimmune diseases? 
o Yes 
o No   
 
69. If yes, witch diseases are included in the screening 
o Celiac disease 
o Hypothyroidism / hyperthyroidism 
o Others:___________________ 
 
70. If yes, how often is the screening performed 
o At each check up 
o Annually  
o Other:_____________________ 
 
 
71. Are there any screening program concerning late diabetes complications among children with 
diabetes? 
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o Yes 
o No 
 
 
72. If yes, what kind of late diabetes complications are included in the screening program among 
children with diabetes? And which methods are used in the screening 
o Retinopathy:___________________________________________ 
o Nephropathy;____________________________________________ 
o Neuropathy:__________________________________________ 
o Angiopathy:__________________________________ 
o Others:__________________________ 
 
73. If yes on question 70, how often is the screening performed 
o At every check up: 
o Annually: 
o Other: _______ 
 
 
Quality of life and mental health 
 
74. What assistance do the children with diabetes and their parents  receive in relation to: 
 
o School 
 
o Hobbies   
 
o Sports 
 
 
75. Are there social activities arranged for the children and their parents?  
 
76. What kind of social activities are arranged? And who organises them? 
 
 
 
77. Have you conducted/do you conduct research on the quality of life in the children with diabetes? 
 
o Yes 
 If yes, can you elaborate 
 
 
o No 
 
78.  Are intoxicants a problem among children with T1D and T2D? 
o Yes 
o What kind of intoxicant? 
o What are the characteristics of these patients (gender, ethnicity, socioeconomic 
status etc) 
o No 
 
Comment: 
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Complications 
 
 
79. What is the incidence (percentage) of acute diabetes complications among children with T1D and 
T2D under the age of 15? 
 
         Type 1 diabetes 
o Diabetic ketoacidosis 
o Severe hypoglycaemia with unconsciousness and/or convulsions 
o Other:___________ 
 
Type 2 diabetes 
o Diabetic ketoacidosis 
o Severe hypoglycaemia with unconsciousness and/or convulsions 
         Other:___________ 
 
80. What is the incidence (%) of long-term complications among children under the age of 15 years? 
And how old are they? 
 
          Type 1 diabetes 
o Retinopathy: 
How many have been treated with laser? 
o Nephropathy: 
o Neuropathy: 
o Hypertension  
How many get anti hypertension treatment? 
 
Type 2 diabetes 
o Retinopathy: 
How many have been treated with laser? 
o Nephropathy: 
o Neuropathy: 
o Hypertension  
How many get anti hypertension treatment? 
 
 
81. What is the incidence (%) of long-term complication among adults who got the diagnosis of 
diabetes before they turned 15 years? 
Type 1 diabetes: 
 
Type 2 diabetes:       
         
      The following must be discussed: 
o How old were the patients when they where diagnosed with diabetes? 
o How many years diabetes duration at onset of the late complication? 
 
o Retinopathy: 
o Nephropathy: 
o Neuropathy: 
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82. Is overweight a problem among children with diabetes? 
 
Type 1 diabetes 
o If yes: 
o Are there any differences between gender, ethnicity, socioeconomic background etc? 
o In which group is the prevalence of overweight highest? 
o What kind of prevention and treatment regimens does the hospital have? 
o Are the treatment regimens effective? 
o Do children with overweight in practice have significant more complications than children 
with normal weight? 
o Are there other problems related to overweight and diabetes? 
 
 
Type 2 diabetes 
o If yes: 
o Are there any differences between gender, ethnicity, socioeconomic background etc? 
o In which group is the prevalence of overweight highest? 
o What kind of prevention and treatment regimens does the hospital have? 
o Are the treatment regimens effective? 
o Do children with overweight in practice have significant more complications than children 
with normal weight? 
o Are there other problems related to overweight and diabetes? 
 
 
 
 
